<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="98996">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01716858</url>
  </required_header>
  <id_info>
    <org_study_id>Chiba_SFN_Openstudy2012</org_study_id>
    <nct_id>NCT01716858</nct_id>
  </id_info>
  <brief_title>An Open Study of Sulforaphane-rich Broccoli Sprout Extract in Patients With Schizophrenia</brief_title>
  <official_title>Sulforaphane for Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiba University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiba University</source>
  <oversight_info>
    <authority>Japan: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Accumulating evidence suggests a role of oxidative stress in the pathophysiology of
      schizophrenia. The potent antioxidant sulforaphane (SFN) is an organosulfur compound derived
      from a glucosinolate precursor found in cruciferous vegetables such as broccoli, Brussels
      sprouts and cabbage. The protection afforded by SFN is thought to be mediated via activation
      of the NF-E2-related factor-2 (Nrf2) pathway and subsequent up-regulation of phase II
      detoxification enzymes and antioxidant proteins, through an enhancer sequence referred to as
      the electrophilic responsive element or antioxidant responsive element. Recently, we
      reported that SFN could attenuate behavioral abnormalities in mice after the NMDA receptor
      antagonist phencyclidine. Considering the potent antioxidant effects of SFN, we have a
      hypothesis that SFN would be a potential therapeutic drug for schizophrenia. The purpose of
      this study is to determine whether SFN-rich broccoli sprout extract have beneficial effects
      in patients with schizophrenia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Positive and Negative Syndrome Scale (PANSS)</measure>
    <time_frame>Change from baseline in PANSS scores at 8-weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cognition using CogState Research Battery</measure>
    <time_frame>Change from baseline in the scores of the battery at 8-weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>A single-arm study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sulforaphane-rich Broccoli Sprout Extract</intervention_name>
    <arm_group_label>A single-arm study</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Schizophrenia for DSM-IV TR criteria

          -  Patients are treated with an antipsychotic drug (risperidone, olanzapine, quetiapine,
             perospirone, aripiprazole, blonanserin, paliperidone).

          -  Patients are stable for 4-weeks for antipsychotic medication.

        Exclusion Criteria:

          -  Patients treated with clozapine

          -  Patients treated with two or more antipsychotic drugs

          -  Pregnant or breast-feeding women

          -  Patients treated with sulforaphane for more than 8-weeks in the past.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masaomi Iyo, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Chairman, Department of Psychiatry, Chiba University Graduate School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Akihiro Shiina, MD, PhD</last_name>
    <phone>+81-43-222-7171</phone>
    <email>shiina-akihiro@faculty.chiba-u.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Masaomi Iyo, MD, PhD</last_name>
    <phone>+81-43-222-7171</phone>
    <email>iyom@faculty.chiba-u.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chiba University Hospital</name>
      <address>
        <city>Chiba</city>
        <zip>260-8670</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akihiro Shiina, MD, PhD</last_name>
      <phone>+81-43-226-7171</phone>
      <email>shiina-akihiro@faculty.chiba-u.jp</email>
    </contact>
    <investigator>
      <last_name>Kenji Hashimoto, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>October 29, 2012</lastchanged_date>
  <firstreceived_date>October 22, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chiba University</investigator_affiliation>
    <investigator_full_name>Kenji Hashimoto</investigator_full_name>
    <investigator_title>Sulforaphane for Schizophrenia</investigator_title>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>Sulforaphane</keyword>
  <keyword>Psychosis</keyword>
  <keyword>Cognition</keyword>
  <keyword>Oxidative stress</keyword>
  <keyword>Antioxidant</keyword>
  <keyword>Anti-inflammatory</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sulforafan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
